Screening of Kabasura Kudineer Chooranam against COVID-19 through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies

GOPALASATHEESKUMAR K, Karthikeyen Lakshmanan, Anguraj Moulishankar, J. Suresh, D. K. Babu, V. Kalaichelvan
{"title":"Screening of Kabasura Kudineer Chooranam against COVID-19 through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies","authors":"GOPALASATHEESKUMAR K, Karthikeyen Lakshmanan, Anguraj Moulishankar, J. Suresh, D. K. Babu, V. Kalaichelvan","doi":"10.2139/ssrn.3625653","DOIUrl":null,"url":null,"abstract":"COVID-19 is the infectious pandemic disease caused by the novel\ncoronavirus. The COVID-19 is spread globally in a short span of\ntime. The Ministry of AYUSH, India which promotes Siddha and\nother Indian system of medicine recommends the use of formulation\nlike Nilavembu Kudineer and Kaba Sura Kudineer Chooranam\n(KSKC). The present work seeks to provide the evidence for the\naction of 74 different constituents of the KSKC formulation acting\non two critical targets. That is main protease and SARS-CoV-2 RNAdependent\nRNA polymerase target through molecular docking studies.\nThe molecular docking was done by using AutoDock Tools 1.5.6 of\nthe 74 compounds, about 50 compounds yielded docking results against\nCOVID-19 main protease while 42 compounds yielded against SARSCoV-\n2 RNA-dependent RNA polymerase. This research has concluded\nthat the KSKC has the lead molecules that inhibits COVID-19’s target\nof main protease of COVID-19 and SARS-CoV-2 RNA-dependent\nRNA polymerase.","PeriodicalId":8846,"journal":{"name":"Asian Journal of Organic & Medicinal Chemistry","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Organic & Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3625653","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

COVID-19 is the infectious pandemic disease caused by the novel coronavirus. The COVID-19 is spread globally in a short span of time. The Ministry of AYUSH, India which promotes Siddha and other Indian system of medicine recommends the use of formulation like Nilavembu Kudineer and Kaba Sura Kudineer Chooranam (KSKC). The present work seeks to provide the evidence for the action of 74 different constituents of the KSKC formulation acting on two critical targets. That is main protease and SARS-CoV-2 RNAdependent RNA polymerase target through molecular docking studies. The molecular docking was done by using AutoDock Tools 1.5.6 of the 74 compounds, about 50 compounds yielded docking results against COVID-19 main protease while 42 compounds yielded against SARSCoV- 2 RNA-dependent RNA polymerase. This research has concluded that the KSKC has the lead molecules that inhibits COVID-19’s target of main protease of COVID-19 and SARS-CoV-2 RNA-dependent RNA polymerase.
靶向SARS-CoV-2主要蛋白酶和RNA依赖性RNA聚合酶筛选Kabasura Kudineer Chooranam抗COVID-19的分子对接研究
COVID-19是由新型冠状病毒引起的传染性大流行疾病。COVID-19在短时间内全球传播。推广悉达和其他印度医学体系的印度阿尤什部建议使用Nilavembu Kudineer和Kaba Sura Kudineer Chooranam(KSKC)等配方。目前的工作旨在为KSKC制剂的74种不同成分对两个关键目标的作用提供证据。这是通过分子对接研究的主要蛋白酶和SARS-CoV-2 rnadependent entrna聚合酶靶点。在74个化合物中,约50个化合物获得了针对covid -19主要蛋白酶的对接结果,42个化合物获得了针对SARSCoV-2 RNA依赖性RNA聚合酶的对接结果。本研究发现,KSKC具有抑制COVID-19主要蛋白酶靶点和SARS-CoV-2 rna依赖性rna聚合酶的先导分子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信